TY - JOUR
T1 - ProteoCure
T2 - A European network to fine-tune the proteome
AU - Coux, Olivier
AU - Farràs, Rosa
AU - Abbas, Mohamad
AU - Barrio, Rosa
AU - Blattner, Christine
AU - Brix, Klaudia
AU - Chachami, Georgia
AU - Chevet, Eric
AU - Clague, Michael J.
AU - Dantuma, Nico
AU - Rankov, Aleksandra Divac
AU - Galdeano, Carles
AU - Giglione, Carmela
AU - Glickman, Michael H.
AU - Lalmanach, Gilles
AU - Lindon, Catherine
AU - Matthiesen, Rune
AU - Meroni, Germana
AU - Pick, Elah
AU - Poidevin, Laetitia
AU - Rivas, Carmen
AU - Rodriguez, Manuel S.
AU - Sammler, Esther
AU - Shiber, Ayala
AU - Skoulakis, Efthimios M.C.
AU - Stein, Matthias
AU - Vertegaal, Alfred C.O.
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/11
Y1 - 2024/11
N2 - Proteins are essential molecular actors in every cellular process. From their synthesis to their degradation, they are subject to continuous quality control mechanisms to ensure that they fulfil cellular needs in proper and timely fashion. Proteostasis is a key process allowing cells or organisms to maintain an appropriate but dynamic equilibrium of their proteome (the ensemble of all their proteins). It relies on multiple mechanisms that together control the level, fate and function of individual proteins, and ensure elimination of abnormal ones. The proteostasis network is essential for development and adaptation to environmental changes or challenges. Its dysfunctions can lead to accumulation of deleterious proteins or, conversely, to excessive degradation of beneficial ones, and are implicated in many diseases such as cancers, neurodegeneration, or developmental and aging disorders. Manipulating this network to control abundance of selected target proteins is therefore a strategy with enormous therapeutic or biotechnological potential. The ProteoCure COST Action gathers more than 350 researchers and their teams (31 countries represented) from the academic, clinical, and industrial sectors, who share the conviction that our understanding of proteostasis is mature enough to develop novel and highly specific therapies based on selective tuning of protein levels. Towards this objective, the Action organizes community-building activities to foster synergies among its participants and reinforce training of the next generation of European researchers. Its ambition is to function as a knowledge-based network and a creative exchange hub on normal and pathologic proteostasis, focusing on developing innovative tools modulating the level of specific protein(s).
AB - Proteins are essential molecular actors in every cellular process. From their synthesis to their degradation, they are subject to continuous quality control mechanisms to ensure that they fulfil cellular needs in proper and timely fashion. Proteostasis is a key process allowing cells or organisms to maintain an appropriate but dynamic equilibrium of their proteome (the ensemble of all their proteins). It relies on multiple mechanisms that together control the level, fate and function of individual proteins, and ensure elimination of abnormal ones. The proteostasis network is essential for development and adaptation to environmental changes or challenges. Its dysfunctions can lead to accumulation of deleterious proteins or, conversely, to excessive degradation of beneficial ones, and are implicated in many diseases such as cancers, neurodegeneration, or developmental and aging disorders. Manipulating this network to control abundance of selected target proteins is therefore a strategy with enormous therapeutic or biotechnological potential. The ProteoCure COST Action gathers more than 350 researchers and their teams (31 countries represented) from the academic, clinical, and industrial sectors, who share the conviction that our understanding of proteostasis is mature enough to develop novel and highly specific therapies based on selective tuning of protein levels. Towards this objective, the Action organizes community-building activities to foster synergies among its participants and reinforce training of the next generation of European researchers. Its ambition is to function as a knowledge-based network and a creative exchange hub on normal and pathologic proteostasis, focusing on developing innovative tools modulating the level of specific protein(s).
KW - COST action
KW - Europe
KW - Proteolysis
KW - Proteostasis
KW - Targeted protein degradation
UR - http://www.scopus.com/inward/record.url?scp=85198337777&partnerID=8YFLogxK
U2 - 10.1016/j.biochi.2024.06.004
DO - 10.1016/j.biochi.2024.06.004
M3 - Short survey
C2 - 38901793
AN - SCOPUS:85198337777
SN - 0300-9084
VL - 226
SP - 4
EP - 9
JO - Biochimie
JF - Biochimie
ER -